In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:

Brief overview of BTC and GEA
Approved HER2-directed therapies for BTC and GEA and their mechanisms of action
Efficacy and toxicities of the approved agents and optimal management strategies
Key ongoing trials of HER2-directed therapies in BTC and GEA
Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA

Presenters

Amit Mahipal, MD, MPH
Director, Gastrointestinal Medical Oncology Program
Ruth and Donald Goodman Endowed Chair in GI Oncology
Professor of Medicine, Senior Attending Physician
University Hospitals Siedman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Shubham Pant, MD
Professor
Department of Gastrointestinal (GI) Medical Oncology
Department of Investigational Cancer Therapeutics
Director of Clinical Research
Associate Director for Early Phase Drug Development
Sheikh Ahmed Bin Zayed Al Nahyan Center
MD Anderson Cancer Center
Houston, Texas

Link to full program:
https://bit.ly/3KL2ank

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options